FMP

FMP

Enter

ZTS - Zoetis Inc.

photo-url-https://images.financialmodelingprep.com/symbol/ZTS.png

Zoetis Inc.

ZTS

NYSE

Zoetis Inc. discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses. The company also offers vaccines, which are biological preparations to prevent diseases of the respiratory, gastrointestinal, and reproductive tracts or induce a specific immune response; anti-infectives that prevent, kill, or slow the growth of bacteria, fungi, or protozoa; and parasiticides that prevent or eliminate external and internal parasites, which include fleas, ticks, and worms. It also provides other pharmaceutical products that comprise pain and sedation, antiemetic, reproductive, and oncology products; dermatology products for itch associated with allergic conditions and atopic dermatitis; and medicated feed additives, which offer medicines to livestock. In addition, the company provides portable blood and urine analysis testing, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, including nutritionals and agribusiness services, as well as products and services in areas, such as biodevices, genetics tests, and precision animal health. It markets its products to veterinarians, livestock producers, and retail outlets, as well as third-party veterinary distributors through its sales representatives, and technical and veterinary operations specialists. The company was founded in 1952 and is headquartered in Parsippany, New Jersey.

157.44 USD

1.79 (1.14%)

ZTS Financial Statements

Quarter

2024 Q4

2024 Q3

2024 Q2

2024 Q1

Total Revenue

2.32B

2.39B

2.36B

2.19B

Cost of Revenue

707M

701M

703M

680M

Gross Profit

1.61B

1.69B

1.66B

1.51B

Operating Expenses

845M

732M

752M

709M

Research and Development

186M

167M

171M

162M

Selling, General & Administrative Expenses

625M

565M

581M

547M

Selling & Marketing Expenses

0

0

0

0

General & Administrative Expenses

0

0

0

0

Other Expenses

34M

0

2M

-5M

Operating Income

765M

920M

906M

801M

Total Other Income/Expenses Net

-33M

-46M

-161M

-91M

Income Before Tax

732M

874M

780M

747M

Income Tax

151M

182M

156M

148M

Net Income

581M

682M

624M

599M

Basic EPS

1.28

1.51

1.37

1.31

EPS Diluted

1.28

1.5

1.37

1.31

Basic Average Shares

450.5M

452.9M

455.5M

458M

Diluted Average Shares

451.1M

453.5M

456M

458.8M

EBITDA

911M

1.06B

1.03B

927M

Retained Earning Schedule

Quarter

2024 Q4

2024 Q3

2024 Q2

2024 Q1

Retained Earnings (Previous Year)

11.81B

11.12B

10.7B

10.29B

Net Income

581M

682M

624M

599M

Stock Repurchases

-553M

-433M

-533M

-339M

Dividend Paid

-194M

-197M

-197M

-198M

Retained Earnings

11.97B

11.81B

11.12B

10.7B

Other Distributions

-585M

52M

-302M

-136M

PPE Schedule

Quarter

2024 Q4

2024 Q3

2024 Q2

2024 Q1

Gross PPE

3.61B

3.52B

3.42B

3.48B

Annual Depreciation

123M

121M

127M

126M

Capital Expenditure

-216M

-167M

-132M

-140M

Net PPE

3.7B

3.57B

3.43B

3.49B

Intangible and Goodwill Schedule

Quarter

2024 Q4

2024 Q3

2024 Q2

2024 Q1

Acquisitions and Adjustments

-20M

5M

-20M

0

Goodwill (Previous Year)

2.74B

2.74B

2.76B

2.76B

Goodwill

2.72B

2.74B

2.74B

2.76B

All figures are in USD.

FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedin
2017-2025 © Financial Modeling Prep